Bicara Therapeutics (BCAX) Other Gross PP&E Adjustments (2023 - 2026)
Bicara Therapeutics posted quarterly Other Gross PP&E Adjustments of -$1.4 million for Q1 2026, down 158.7% year-on-year from $2.4 million in Q1 2025, and up 75.29% on a QoQ basis from -$5.8 million in Q4 2025.
Bicara Therapeutics (BCAX) has 4 years of Other Gross PP&E Adjustments data on file, last reported at -$1.4 million in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments fell 158.7% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at -$1.4 million (down 158.7% YoY), and the FY2025 full-year result was -$5.8 million, down 185.33% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at -$1.4 million, up from -$5.8 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$414000.0 in Q3 2024 and bottomed at -$5.8 million in Q4 2025.
- The 4-year median for Other Gross PP&E Adjustments is -$1.7 million (2025), against an average of -$1.9 million.
- The widest annual swing landed in 2024, when Other Gross PP&E Adjustments sank 120.11%; it then tumbled 375.6% in 2025.
- A 4-year view of Other Gross PP&E Adjustments shows it stood at -$920000.0 in 2023, then plunged by 120.11% to -$2.0 million in 2024, then tumbled by 185.33% to -$5.8 million in 2025, then jumped by 75.29% to -$1.4 million in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$1.4 million (Q1 2026), -$5.8 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Bicara Therapeutics | 1.25 Bn | 1.25 Bn | - | -1.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.43 Mn |
| Mar 31, 2026 | -1.43 Mn |
| Dec 31, 2025 | -5.78 Mn |
| Dec 31, 2025 | -5.78 Mn |
| Sep 30, 2025 | -1.97 Mn |
| Sep 30, 2025 | -1.97 Mn |
| Jun 30, 2025 | -2.24 Mn |
| Jun 30, 2025 | -2.24 Mn |
| Mar 31, 2025 | -552,000.00 |
| Mar 31, 2025 | -552,000.00 |
| Dec 31, 2024 | -2.03 Mn |
| Dec 31, 2024 | -2.03 Mn |
| Sep 30, 2024 | -414,000.00 |
| Sep 30, 2024 | -414,000.00 |
| Dec 31, 2023 | -920,000.00 |
| Dec 31, 2023 | -920,000.00 |